Recently published in Science Translational Medicine, findings first-authored by Marie-Eve Beaulieu evidence the Omomyc mini-protein as the first efficient and tolerable MYC inhibitor for the treatment of non-small cell lung cancer (NSCLC) – one of the most difficult-to-treat cancers for both women and men.
This translational study, led by VHIO’s Laura Soucek, Principal Investigator of our Mouse Models of Cancer Therapies Group, represents an important forward step in driving the Omomyc mini-protein closer to the clinic. VHIO Communications caught up with Laura and Marie-Eve last week for a Q&A round to discuss their research and its relevance in advancing precision medicine in oncology.
To watch our video and discover just how the successful intravenous systemic administration of Omomyc against non-small cell lung cancer is bringing this novel anti-cancer therapy closer to the clinic for the more effective treatment of multiple tumor types, please click below:
[fusion_youtube id=”https://youtu.be/5RzvGsHmKKc” width=”800″ height=”450″ autoplay=”false” api_params=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=””][/fusion_youtube]
To access our corresponding VHIO news article click here.
